KaliVir Announces Opening of GMP Cleanroom Facility, Increasing Manufacturing Capacity for Oncolytic Viruses
KaliVir Immunotherapeutics Announces FDA Clearance of Investigational New Drug (IND) for Systemic Oncolytic Virus ASP1012 for Phase I Clinical Trials for Locally Advanced or Metastatic Solid Tumors
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Superior Therapeutic Efficacy of VET3-TGI at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
KaliVir Immunotherapeutics Appoints Viral Immunotherapy Researcher Grant McFadden, Ph.D., to its Board of Directors
KaliVir Immunotherapeutics Announces Presentation at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
KaliVir Immunotherapeutics Announces New In Vivo Data Demonstrating Potent Therapeutic Activity for Oncolytic Therapy VET3-TGI at the American Association for Cancer Research (AACR) Annual Meeting
KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
KaliVir Appoints Industry Veteran Adina Pelusio as Senior Vice President of Clinical Operations to Lead Clinical Development Pipeline
